Anesthesiology Journal's podcast
Anesthesiology, the journal of the American Society of Anesthesiologists
Audio interviews and overviews of articles covered in the journal.
Episodes
Mentioned books
Aug 4, 2025 • 13min
September 2025 Editor-in-Chief Podcast
Creator: James P. Rathmell, M.D. September 2025, Volume 143, Issue 3 Overview of September issue original studies. Transcript
Jul 21, 2025 • 35min
Featured Author Podcast: Nitric Oxide in High Risk Cardiac Surgery
Moderator: James P. Rathmell, M.D. Participants: Nikolay O. Kamenshchikov, M.D. and Lorenzo Berra, M.D. and Kamrouz Ghadimi, M.D. Articles Discussed: Perioperative Nitric Oxide Conditioning Reduces Acute Kidney Injury in Cardiac Surgery Patients with Chronic Kidney Disease (the DEFENDER Trial): A Randomized Controlled Trial Nitric Oxide and Kidney Injury after Cardiac Surgery: A Solution Looking for a Problem
Jul 1, 2025 • 22min
Featured Author Podcast: Pediatric Quality of Recovery Scale
Moderator: James P. Rathmell, M.D. Participants: Paul Lee-Archer and Clyde Matava, M.B.Ch.B., M.Med., M.H.S.C. Articles Discussed: Development of the Pediatric Scale for Quality of Recovery (PedSQoR) Measuring what Matters - the Pediatric Scale for Quality of Recovery
Jul 1, 2025 • 14min
August 2025 Editor-in-Chief Podcast
Creator: James P. Rathmell, M.D. August 2025, Volume 143, Issue 2 Overview of August issue original studies. Transcript
Jun 4, 2025 • 17min
Featured Author Podcast: Patient Blood Management and Surgical Outcomes
Douglas Colquhoun, an Assistant Professor at the University of Michigan Medical School, shares insights on Patient Blood Management (PBM) during surgery. He discusses how rigorous adherence to PBM guidelines can significantly reduce postoperative complications, particularly in hip and knee arthroplasties. The conversation touches on the link between effective PBM practices and lower rates of major cardiac events, as well as the challenges of integrating these protocols into healthcare systems. Cost-effectiveness in PBM techniques is also explored, prompting a reevaluation of surgical practices.
Jun 2, 2025 • 41min
Featured Author Podcast: Uterine Tone and Severe Postpartum Hemorrhage
Moderator: BobbieJean Sweitzer, M.D. Participants: Jessica R Ansari, M.D., M.S. and Craig M. Palmer, M.D. Articles Discussed: Uterine Tone Numeric Rating Score as an Early Indicator of Major Postpartum Hemorrhage During Cesarean Delivery: A Prospective Observational Study Predicting the Unpredictable: A New Approach to Predict Postpartum Hemorrhage from Uterine Atony Transcript
Jun 2, 2025 • 12min
July 2025 Editor-in-Chief Podcast
Creator: James P. Rathmell, M.D. July 2025, Volume 143, Issue 1 Overview of July issue original studies. Transcript
May 19, 2025 • 21min
Featured Author Podcast: Suzetrigine for the Treatment of Acute Pain
Moderator: James P. Rathmell, M.D. Participants: Carmen Bozic, M.D. Articles Discussed: Suzetrigine, a Nonopioid NaV1.8 Inhibitor for Treatment of Moderate-to-severe Acute Pain: Two Phase 3 Randomized Clinical Trials Suzetrigine: First in a New Class of Nonopioid Analgesics for Acute Pain Transcript
May 7, 2025 • 21min
Featured Author Podcast: Danavorexton Promotes Respiration and Wakefulness
Moderator: James P. Rathmell, M.D. Participants: Rebecca L. Wu, M.D. and Max B. Kelz, M.D., Ph.D. Articles Discussed: TAK-925 (danavorexton), an Orexin Receptor 2 Agonist, Reduces Opioid-Induced Respiratory Depression and Sedation Without Affecting Analgesia in Healthy Adult Males Alluring Potential to Accelerate Emergence and Ameliorate Opioid-induced Respiratory Depression without Antagonizing Analgesia: Danavorexton Enters the Anesthetic Landscape Transcript
May 7, 2025 • 35min
Featured Author Podcast: Sugammadex Use in Renal Impairment
Moderator: BobbieJean, M.D. Participants: Douglas Colquhoun, M.B., M.Sc., M.P.H. and Stephan R. Thilen Articles Discussed: Neuromuscular Blockade and Antagonism in Patients with Renal Impairment: A Multicenter Retrospective Cross Sectional Study On and Off Label Use of Sugammadex in Patients with Renal Impairment in the 6 ½ Years Following FDA Approval Transcript


